XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

12. Stock-Based Compensation

In May 2021, the Company’s board of directors adopted, and its stockholders approved, the 2021 Equity Incentive Plan (the “2021 Plan”), which became effective in connection with the IPO. The 2021 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company's employees and any of its parent or subsidiary corporations’ employees, and for the grant of non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, and performance awards to the Company’s employees, directors and consultants and any of its parent or subsidiary corporations’ employees and consultants. A total of 10,459,000 shares of the Company’s Class A common stock have been reserved for issuance under the 2021 Plan in addition to (i) an annual increase of 4% of the outstanding shares of the Company's common stock, with Class A and Class B common stock taken together, on the first day of each fiscal year ( the "Evergreen Addition") and (ii) upon the expiration, forfeiture, cancellation, or reacquisition of any shares of Class B common stock underlying outstanding stock awards granted under the 2012 Equity Incentive Plan, an equal number of shares of Class A common stock, such number of shares not to exceed 7,563,990. On January 1, 2022, pursuant to the Evergreen Addition, 4,825,566 shares of Class A common stock were added to the 2021 Plan issuance reserve. At September 30, 2022, there were 14,075,898 remaining shares available for the Company to grant under the 2021 Plan.

Stock Options

A summary of the Company’s option activity during the nine months ended September 30, 2022 was as follows (in thousands, except share and per share amounts):

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Weighted-

 

 

Average

 

 

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

 

Options

 

 

Exercise Price

 

 

Contractual

 

 

Intrinsic

 

 

 

Outstanding

 

 

per Share

 

 

Life (years)

 

 

Value

 

Outstanding at December 31, 2021

 

 

6,849,910

 

 

$

5.05

 

 

 

4.98

 

 

$

205,010

 

Options granted

 

 

 

 

 

 

 

 

 

 

 

 

Options exercised

 

 

(2,282,645

)

 

 

0.64

 

 

 

 

 

 

 

Options forfeited

 

 

(210,104

)

 

 

8.66

 

 

 

 

 

 

 

Outstanding at September 30, 2022

 

 

4,357,161

 

 

$

7.19

 

 

 

5.88

 

 

$

11,041

 

Exercisable at September 30, 2022

 

 

3,294,854

 

 

$

6.72

 

 

 

5.61

 

 

$

9,900

 

There were no options granted during the three or nine months ended September 30, 2022. There were no options granted during the three months ended September 30, 2021. The weighted average grant date fair value of options granted during the nine months ended September 30, 2021 was $7.21. Aggregate intrinsic value represents the difference between the exercise price of the options and the fair value of the Company’s common stock.

There were no options granted during the three months ended September 30, 2021. The fair value of options granted during the nine months ended September 30, 2021 was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2021

 

2021

 

 

 

 

 

 

 

Dividend yield

 

 

 

 

0.0

%

Risk-free interest rate

 

 

 

0.3 % - 0.8%

 

Expected term (in years)

 

 

 

 

5

 

Expected volatility

 

 

 

 

38.0

%

 

Restricted Stock Units (“RSUs”)

A summary of the Company’s RSU activity during the nine months ended September 30, 2022 was as follows:

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Number of

 

 

Grant Date

 

 

 

 

 

 

 

RSU's Outstanding

 

 

Fair Value

 

Awarded and unvested at December 31, 2021

 

 

 

 

 

 

513,547

 

 

$

25.93

 

Awards granted

 

 

 

 

 

 

1,142,491

 

 

 

15.37

 

Awards vested

 

 

 

 

 

 

(68,096

)

 

 

26.08

 

Awards forfeited

 

 

 

 

 

 

(150,076

)

 

 

17.80

 

Awarded and unvested at September 30, 2022

 

 

 

 

 

 

1,437,866

 

 

$

18.38

 

The fair value of RSU grants is determined based upon the market closing price of the Company's Class A common stock on the date of grant. RSUs vest over the requisite service period, which ranges between four years and five years from the date of grant, subject to continued employment for employees and provision of services for nonemployees.

Stock-based compensation expense included in the condensed consolidated statements of operations was as follows (in thousands):

 

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Cost of revenue

 

 

 

 

 

$

 

 

$

 

 

$

 

 

$

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

 

 

 

 

507

 

 

 

110

 

 

 

1,080

 

 

 

141

 

Sales and marketing

 

 

 

 

 

 

612

 

 

 

56

 

 

 

1,062

 

 

 

92

 

General and administrative

 

 

 

 

 

 

883

 

 

 

588

 

 

 

2,480

 

 

 

1,652

 

Total stock-based compensation

 

 

 

 

 

$

2,002

 

 

$

754

 

 

$

4,622

 

 

$

1,885

 

At September 30, 2022, there was $2.8 million of total unrecognized compensation cost related to unvested stock options granted under the 2012 Equity Incentive Plan and the 2021 Plan, which is expected to be recognized over a remaining weighted-average period of 1.6 years.

At September 30, 2022, there was $24.3 million of total unrecognized compensation cost related to unvested RSUs granted under the 2021 Plan, which is expected to be recognized over a remaining weighted-average period of 3.7 years.